AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A medicament for treating addiction craving, characterized in that the medicament consists of a combination of two administration forms, one of the administration forms continuously releasing at least one modulator of nicotinic receptors, which is selected from the group consisting of galanthamine and the pharmacologically acceptable salts of galanthamine, and the other administration form enabling a rapid entry of galanthamine or one of its pharmacologically acceptable salts into the central nervous system, wherein the administration form enabling a quick entry of galanthamine or a pharmacologically acceptable salt of galanthamine into the central nervous system is selected from the group consisting of: buccal solutions, spray solutions and drip solutions.

2. (Canceled).

3. (Previously Presented) The medicament according to claim 1, characterized in that the administration form continuously releasing the modulator or the modulators of nicotinic receptors is selected from the group consisting of transdermal therapeutic systems, subcutaneous implants and intramuscularly injectable preparations.

4. (Previously Presented) The medicament according to claim 3, characterized in that the intramuscularly injectable preparation is a suspension of microcapsules containing the modulator or the modulators of nicotinic receptors.

5. (Currently Amended) The medicament according to claim 3, characterized in that the administration form continuously releasing the modulator or modulators of nicotinic receptors releases between 10 mg and 25 mg of galanthamine or a pharmacologically acceptable salt of galanthamine, ~~or between 5 mg and 50 mg of nicotine or a pharmacologically acceptable salt of nicotine,~~ per day.

6. (Previously Presented) The medicament according to claim 1, characterized in that the administration form enabling a quick entry of galanthamine or a pharmacologically acceptable salt of galanthamine into the central nervous system contains galanthamine or a pharmacologically acceptable salt of galanthamine in an amount of from 1 to 5 mg.

7. (Cancelled)

8. (Previously Presented) The medicament according to claim 1, characterized in that the administration form which enables a rapid entry of galanthamine or a pharmacologically acceptable salt of galanthamine into the central nervous system is in the form of a flexible plastic container with a capacity of between 1 and 5 ml.

9. (Currently Amended) The medicament according to claim 8, characterized in that the plastic container is provided with nozzles through which the solution is ~~capable of being~~ sprayed or dripped into the nose.

10. (Withdrawn, Currently Amended) A method for treating substance craving by modulation of neuronal nicotinic receptors, characterized in that it is a two-stage method wherein a permanent treatment with a pharmaceutical administration form which continuously delivers a modulator of nicotinic receptors, which is selected from the group consisting of galanthamine and the pharmacologically acceptable salts of galanthamine, is supplemented upon the appearance of a strong craving for a substance by administering galanthamine or a pharmacologically acceptable salt thereof by means of an administration form which enables rapid entry of galanthamine or of a pharmaceutically acceptable salt thereof into the central nervous system, wherein the administration form enabling rapid entry of galanthamine or of a pharmacologically acceptable salt of galanthamine into the central nervous system is selected from the group consisting of: buccal solutions, spray solutions and drip solutions.

11. (Withdrawn) The method according to claim 10, characterized in that the substance craving is a craving for alcoholic beverages and/or tobacco products.

12. (Cancelled).

13. (Withdrawn) The method according to claim 10, characterized in that the administration form releasing the modulator or the modulators of nicotinic receptors continuously is selected from the group consisting of transdermal therapeutic systems, subcutaneous implants and intramuscularly injectable preparations.

14. (Withdrawn) The method according to claim 13, characterized in that the subcutaneously injectable preparation is a suspension of microcapsules containing the modulator or modulators of nicotinic receptors for intramuscular injection.

15. (Withdrawn, Currently Amended) The method according to claim 13, characterized in that the administration form continuously releasing the modulator or modulators of nicotinic receptors releases between 10 mg and 25 mg of galanthamine or a pharmacologically acceptable salt of galanthamine, ~~or between 5 mg and 50 mg of nicotine or a pharmacologically acceptable salt of nicotine,~~ per day.

16. (Withdrawn) The method according to claim 10, characterized in that the administration form enabling a quick entry of galanthamine or of a pharmacologically acceptable salt of galanthamine into the central nervous system contains galanthamine or a pharmacologically acceptable salt of galanthamine in an amount of from 1 to 5 mg.

17. (Cancelled)

18. (Withdrawn) The method according to claim 10 characterized in that the administration form which enables a rapid entry of galanthamine or of a pharmacologically acceptable salt of galanthamine into the central nervous system is in the form of a flexible plastic container with a capacity of between 1 and 5 ml.

19. (Withdrawn, Currently Amended) The method according to claim 18 characterized in that the plastic container is provided with nozzles through which the solution is ~~capable of being~~ sprayed or dripped into the nose.

20. (Previously Presented) The medicament according to claim 1, wherein the two administration forms are administered independently.

21. (Previously Presented) The medicament according to claim 2, wherein the modulator of nicotinic receptors in the administration form continuously releasing the modulator is galanthamine.

22. (Withdrawn) The method according to claim 12, wherein the modulator of nicotinic receptors in the administration form continuously releasing the modulator is galanthamine.